PMID- 22862816
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 1744-859X (Electronic)
IS  - 1744-859X (Linking)
VI  - 11
IP  - 1
DP  - 2012 Aug 3
TI  - Assessment of pharmacological strategies for management of major depressive 
      disorder and their costs after an inadequate response to first-line 
      antidepressant treatment in primary care.
PG  - 22
LID - 10.1186/1744-859X-11-22 [doi]
AB  - BACKGROUND: The aim of the study was to determine the most common treatment 
      strategies and their costs for patients with an inadequate response to first-line 
      antidepressant treatment (AD) in primary care. METHOD: A retrospective cohort 
      study of medical records from six primary care centers was conducted. Adults with 
      a major depressive disorder diagnosis, at least 8 weeks of AD treatment after the 
      first prescription, and patient monitoring for 12 months were analyzed. 
      Healthcare (direct cost) and non-healthcare costs (indirect costs; work 
      productivity losses) were described. RESULTS: A total of 2,260 patients were 
      studied. Forty-three percent of patients (N = 965) presented an inadequate 
      response to treatment. Summarizing the different treatment approaches: 43.2% were 
      switched to another AD, 15.5% were given an additional AD, AD dose was increased 
      in 14.6%, and 26.7% remained with the same antidepressant agent. 
      Healthcare/annual costs were 451.2 Euros for patients in remission vs. 826.1 
      Euros in those with inadequate response, and productivity losses were 991.4 
      versus 1,842.0 Euros, respectively (p < 0.001). CONCLUSION: Antidepressant switch 
      was the most common therapeutic approach performed by general practitioners in 
      naturalistic practice. A delay in treatment change when no remission occurs and a 
      significant heterogeneity in management of these patients were also found.
FAU - Sicras-Mainar, Antoni
AU  - Sicras-Mainar A
AD  - AstraZeneca Medical Department, Madrid, Spain. 
      jorgealejandro.maurino@astrazeneca.com.
FAU - Maurino, Jorge
AU  - Maurino J
FAU - Cordero, Luis
AU  - Cordero L
FAU - Blanca-Tamayo, Milagrosa
AU  - Blanca-Tamayo M
FAU - Navarro-Artieda, Ruth
AU  - Navarro-Artieda R
LA  - eng
PT  - Journal Article
DEP - 20120803
PL  - England
TA  - Ann Gen Psychiatry
JT  - Annals of general psychiatry
JID - 101236515
PMC - PMC3426459
EDAT- 2012/08/07 06:00
MHDA- 2012/08/07 06:01
PMCR- 2012/08/03
CRDT- 2012/08/07 06:00
PHST- 2012/05/30 00:00 [received]
PHST- 2012/07/30 00:00 [accepted]
PHST- 2012/08/07 06:00 [entrez]
PHST- 2012/08/07 06:00 [pubmed]
PHST- 2012/08/07 06:01 [medline]
PHST- 2012/08/03 00:00 [pmc-release]
AID - 1744-859X-11-22 [pii]
AID - 10.1186/1744-859X-11-22 [doi]
PST - epublish
SO  - Ann Gen Psychiatry. 2012 Aug 3;11(1):22. doi: 10.1186/1744-859X-11-22.